Larsucosterol (Synonyms: DUR-928)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
Larsucosterol  (Synonyms: DUR-928)

Larsucosterol (DUR-928) 是一种胆固醇代谢物，是一种有效的肝 X 受体 (LXR) 拮抗剂。Larsucosterol 是一种有效的内源性脂肪生成调节剂。Larsucosterol 通过降低 mRNA 水平和抑制 SREBP-1 的激活抑制胆固醇的生物合成。

Larsucosterol (Synonyms: DUR-928)

Larsucosterol Chemical Structure

CAS No. : 884905-07-1

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Larsucosterol 的其他形式现货产品:

Larsucosterol (trimethylamine)

Larsucosterol 相关产品

•同靶点产品:

•同靶点蛋白产品:

生物活性

Larsucosterol (DUR-928), a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol as a potent endogenous regulator decreases lipogenesis. Larsucosterol inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1[1][2][3].

体外研究
(In Vitro)

Larsucosterol (DUR-928; 0-25 μM; 8 h; HepG2 cells) inhibits cholesterol biosynthesis by decreasing HMG-CoA reductase mRNA levels and decreases free [14C] cholesterol in a dose-dependent manner[1].
Larsucosterol (0-25 μM; 6 h; HepG2 cells) inhibits HMG-CoA reductase expression by inhibition of both SREBP1 activation and expression in hepatocytes[1].
Larsucosterol (0-50 μM; 48 h) increases cell proliferation and decreases apoptosis in macrophages[2].
Larsucosterol (0-25 μM; 48 h; macrophages) inhibits activation of liver oxysterol receptor LXRα[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Larsucosterol 相关抗体:

Cell Proliferation Assay[2]

Cell Line: Macrophages
Concentration: 0, 5, 10, 15, 20, and 25 μM
Incubation Time: 48 hours
Result: Induces cell proliferation and relative cell number after treatment for 48 h were 120% at 25 μM.

Apoptosis Analysis[2]

Cell Line: Macrophages
Concentration: 0, 5, 10, 15, 20, and 25 μM
Incubation Time: 48 hours
Result: Did not significantly affect the numbers of apoptotic or live cells.

Western Blot Analysis[1]

Cell Line: HepG2 cells
Concentration: 0, 3, 6, 12, and 25 μM
Incubation Time: 6 hours
Result: Inhibited the activation of SREBP-1 and SREBP-2, and subsequently inhibit the expression HMG-CoA reductase.

Western Blot Analysis[2]

Cell Line: Macrophages
Concentration: 0, 3, 6, 12, and 25 μM
Incubation Time: 48 hours
Result: Decreased LXRα levels in the nuclei in a does-dependent manner.

体内研究
(In Vivo)

Larsucosterol (DUR-928; 25 mg/kg; i.p.; twice in 14 hours; C57BL/6J mice with nonalcoholic fatty liver diseases (NAFLD) model) reduces serum lipid levels in mice fed a high-fat diet[3].
Larsucosterol (25 mg/kg; i.p.; twice in 14 hours; C57BL/6J mice with nonalcoholic fatty liver diseases (NAFLD) model) suppressed the expression of the genes and inhibits ABCA1 expressionde. Larsucosterolcreases nuclear SREBP-1 Protein levels and cytoplasmic FAS and ACC1 protein levels in liver tissue[3].
Larsucosterol (25 mg/kg; i.p.; once every 3 days for 6 weeks; C57BL/6J mice with nonalcoholic fatty liver diseases (NAFLD) model) protects the liver from injury by suppressing hepatic inflammation[3].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female C57BL/6J mice with nonalcoholic fatty liver diseases (NAFLD) model[3]
Dosage: 25 mg/kg
Administration: Intraperitoneal injection; once every 3 days for 6 weeks
Result: Decreased plasma cholesterol levels.
Reduced serum alkaline phosphatase, ALT, and AST levels.
Animal Model: Female C57BL/6J mice with nonalcoholic fatty liver diseases (NAFLD) model[3]
Dosage: 25 mg/kg
Administration: Intraperitoneal injection; twice in 14 hours
Result: Decreased plasma TG, CHOL, and HDL-C by 40, 15, and 20%, respectively.
Reduced the mRNA levels of SREBP-1c, ACC1, and FAS by 46, 57, and 49%, respectively.
Suppressed ABCA1 expression.
Suppressed nuclear SREBP-1, cytoplasmic ACC1, and FAS protein levels by 74, 58, and 47%, respectively.

Clinical Trial

分子量

482.72

Formula

C27H46O5S
CAS 号

884905-07-1
结构分类
  • Steroids
初始来源
  • 内源性代谢物
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (534 KB) 产品使用指南 (1538 KB)

参考文献

  • [1]. Ren S, et, al. Sulfated oxysterol, 25HC3S, is a potent regulator of lipid metabolism in human hepatocytes. Biochem Biophys Res Commun. 2007 Sep 7;360(4):802-8.  [Content Brief]

    [2]. Ma Y, et, al. 25-Hydroxycholesterol-3-sulfate regulates macrophage lipid metabolism via the LXR/SREBP-1 signaling pathway. Am J Physiol Endocrinol Metab. 2008 Dec;295(6):E1369-79.  [Content Brief]

    [3]. Xu L, et, al. 5-cholesten-3β,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model. Mol Pharmacol. 2013 Mar;83(3):648-58.  [Content Brief]

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务